Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Mecasermin (Increlex) Peptide
Recombinant human IGF-1 for severe primary IGF-1 deficiency.
What is Mecasermin (Increlex)?
Mecasermin (Increlex) is a igf-1 · endocrine peptide studied for severe primary igf-1 deficiency and growth failure with gh gene deletion and neutralizing gh antibodies. Below is an educational overview of Mecasermin (Increlex) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Increlex
Severe primary IGF-1 deficiency in children and GH gene deletion with anti-GH antibodies.
A twice-daily injection of recombinant IGF-1 — given with a meal — that supports growth in children whose bodies don't make IGF-1.
- •Hypoglycemia (must take with food)
- •Tonsillar hypertrophy / snoring
- •Injection-site lipohypertrophy
- •Ear infections
- •Severe hypoglycemia
- •Intracranial hypertension
- •Tonsillar enlargement leading to sleep apnea
- •Theoretical increase in benign and malignant neoplasms
- •Active or suspected cancer
- •Closed epiphyses (when used for growth)
- •Allergy to mecasermin
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Mecasermin (Increlex) Mechanism of Action
Recombinant human insulin-like growth factor-1 (rhIGF-1) that binds IGF-1 receptors to promote linear growth in children with severe primary IGF-1 deficiency or GH gene deletion with anti-GH antibodies.
Mecasermin (Increlex) Research Areas & Benefits
Mecasermin (Increlex) Dosage & Common Research Protocols
0.04–0.12 mg/kg SC twice daily, given with a meal/snack.
Protocols summarized for educational reference from published research. Not dosing guidance.
Mecasermin (Increlex) Studies & Cited Research
Mecasermin in severe primary IGFD
Improved height velocity over multi-year follow-up.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Mecasermin (Increlex) Side Effects & Safety Considerations
- •FDA-approved.
- •Hypoglycemia — must be taken with food.
- •Tonsillar hypertrophy, intracranial hypertension reported.
Common questions about Mecasermin (Increlex)
More Performance peptides · See all 14
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.